|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01099 SINOPHARM
Nominal 
20.050 -0.500 (-2.433%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 596,569,565 | 8.045% | 552,147,550 | 521,051,235 | 456,414,611 | 425,272,726 |
| Cost of Sales | (548,057,887) | 8.588% | (504,713,490) | (477,000,627) | (416,091,300) | (387,741,423) |
| Gross Profit | 48,511,678 | 2.272% | 47,434,060 | 44,050,608 | 40,323,311 | 37,531,303 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | (598,478) | (750,224) | (416,391) | |
| Profit / (Loss) on Disposal | (2,067,764) | 6.797% | (1,936,170) | (1,130,821) | (1,273,561) | (1,950,177) | |
| Other Non-operating Items | 625,967 | 660.795% | 82,278 | (375,813) | (202,327) | (120,544) | |
| Share of Results of Asso. & JCEs | 1,107,349 | 3.775% | 1,067,067 | 1,069,868 | 987,463 | 887,074 | |
| Profit / (Loss) before Taxation | 19,512,137 | 5.108% | 18,563,819 | 17,003,162 | 15,598,096 | 13,759,810 | |
| Taxation | (4,502,309) | 6.731% | (4,218,377) | (3,938,389) | (3,500,805) | (3,139,738) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (5,956,068) | 2.342% | (5,819,787) | (5,306,127) | (4,910,013) | (4,367,535) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 9,053,760 | 6.194% | 8,525,655 | 7,758,646 | 7,187,278 | 6,252,537 | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 2,430,374 | -23.813% | 3,189,992 | 3,402,869 | 2,944,189 | 3,137,424 |
| Depreciation & Amortisation | 4,430,248 | 6.368% | 4,165,019 | 3,922,058 | 3,597,114 | 3,114,076 |
| Directors' Emoluments | 14,991 | 3.272% | 14,516 | 15,277 | 21,942 | 25,462 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | 290.000 | 6.227% | 273.000 | 249.000 | 231.000 | 211.000 |
| DPS (cts) | 87.000 | -- | 82.000 | 75.000 | 69.000 | 60.000 |
| Dividend Payout Ratio (%) | 30.000% | -- | 30.037% | 30.120% | 29.870% | 28.436% |
| Cash flow per share ($) | 5.510 | -- | 6.726 | 2.983 | 3.585 | 6.323 |
| NBV per share ($) | 23.900 | -- | 21.812 | 19.831 | 18.060 | 15.958 |
| Remarks: | Real time quote last updated: 22/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 3,703,875 |
| %Change | -9.759% |
| EPS / (LPS) | RMB 1.190 |
| NBV Per Share (¥) | RMB 24.207 |